Castration-resistant prostate cancer: Targeting androgen metabolic pathways in recurrent disease

Urologic Oncology: Seminars and Original Investigations

Volumn 27, Issue 3, 2009, Pages 251-257

  Mostaghel, Elahe A ^a   Montgomery, Bruce ^a   Nelson, Peter S ^a  

^a Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Androgen metabolism; Castration resistant; Hormone therapy; Intracrinology; Metastatic; Prostate cancer; Steroidogenesis

Indexed keywords

ABIRATERONE; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BICALUTAMIDE; DUTASTERIDE; ESTROGEN RECEPTOR; FINASTERIDE; FLUTAMIDE; GLUTETHIMIDE; KETOCONAZOLE; PRASTERONE SULFATE; PREGNENOLONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; STERYL SULFATASE; TESTOSTERONE;

ANDROGEN BLOOD LEVEL; ANDROGEN DEPRIVATION THERAPY; ANDROGEN METABOLISM; ANDROGEN SYNTHESIS; CANCER CELL CULTURE; CANCER RESISTANCE; CANCER SURVIVAL; CASTRATION; ENDOCRINE FUNCTION; ENZYME ACTIVITY; ENZYME METABOLISM; GLEASON SCORE; HUMAN; INHIBITION KINETICS; MONOTHERAPY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROTEIN EXPRESSION; RADIOIMMUNOASSAY; RECURRENT CANCER; RECURRENT DISEASE; REVIEW; SURVIVAL RATE; SURVIVAL TIME; TESTOSTERONE BLOOD LEVEL; THERAPY EFFECT; TISSUE HOMOGENATE;

ANDROGEN ANTAGONISTS; ANDROGENS; ENZYME INHIBITORS; FINASTERIDE; HUMANS; MALE; METABOLIC NETWORKS AND PATHWAYS; NEOPLASM RECURRENCE, LOCAL; ORCHIECTOMY; PROSTATIC NEOPLASMS;

EID: 65349151253     PISSN: 10781439     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.urolonc.2009.03.016     Document Type: Review

References (56)

1. Huggins C., and Hodges C.V. Studies on prostate cancer. 1: The effect of castration, of estrogen, and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1 (1941) 293-297
2. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
3. Debes J.D., Comuzzi B., Schmidt L.J., et al. p300 Regulates androgen receptor-independent expression of prostate-specific antigen in prostate cancer cells treated chronically with interleukin-6. Cancer Res 65 (2005) 5965-5973
4. Gao H., Ouyang X., Banach-Petrosky W.A., et al. Emergence of androgen independence at early stages of prostate cancer progression in nkx3.1; PTEN mice. Cancer Res 66 (2006) 7929-7933
5. Chen C.D., Welsbie D.S., Tran C., et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 10 (2004) 33-39 (Epub 2003 Dec. 21)
6. Geller J., Liu J., Albert J., et al. Relationship between human prostatic epithelial cell protein synthesis and tissue dihydrotestosterone level. Clin Endocrinol (Oxf) 26 (1987) 155-161
7. Liu J., Albert J., and Geller J. Effects of androgen blockade with ketoconazole and megestrol acetate on human prostatic protein patterns. Prostate 9 (1986) 199-205
8. Liu J., Geller J., Albert J., et al. Acute effects of testicular and adrenal cortical blockade on protein synthesis and dihydrotestosterone content of human prostate tissue. J Clin Endocrinol Metab 61 (1985) 129-133
9. Labrie F., Dupont A., Belanger A., et al. Combination therapy with flutamide and castration (LHRH agonist or orchiectomy) in advanced prostate cancer: A marked improvement in response and survival. J Steroid Biochem 23 (1985) 833-841
10. Geller J., Albert J., Nachtsheim D., et al. Steroid levels in cancer of the prostate-markers of tumor differentiation and adequacy of anti-androgen therapy. Prog Clin Biol Res 33 (1979) 103-111
11. Geller J., Albert J., and Vik A. Advantages of total androgen blockade in the treatment of advanced prostate cancer. Semin Oncol 15 (1988) 53-61
12. Geller J. Review of assessment of total androgen blockade as treatment of metastatic prostate cancer. J Endocrinol Invest 14 (1991) 881-891
13. Mohler J.L., Gregory C.W., Ford III O.H., et al. The androgen axis in recurrent prostate cancer. Clin Cancer Res 10 (2004) 440-448
14. Nishiyama T., Hashimoto Y., and Takahashi K. The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer. Clin Cancer Res 10 (2004) 7121-7126
15. Nishiyama T., Ikarashi T., Hashimoto Y., et al. The change in the dihydrotestosterone level in the prostate before and after androgen deprivation therapy in connection with prostate cancer aggressiveness using the Gleason score. J Urol 178 (2007) 1282-1289
16. Mostaghel E.A., Page S.T., Lin D.W., et al. Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: Therapeutic implications for castration-resistant prostate cancer. Cancer Res 67 (2007) 5033-5041
17. Page S.T., Lin D.W., Mostaghel E.A., et al. Persistent intraprostatic androgen concentrations after medical castration in healthy men. J Clin Endocrinol Metab 91 (2006) 3850-3856
18. Stanbrough M., Bubley G.J., Ross K., et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66 (2006) 2815-2825
19. Montgomery R.B., Mostaghel E.A., Vessella R., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: A mechanism for castration-resistant tumor growth. Cancer Res 68 (2008) 4447-4454
20. Gregory C.W., Johnson Jr. R.T., Mohler J.L., et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 61 (2001) 2892-2898
21. Culig Z., Hoffmann J., Erdel M., et al. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Br J Cancer 81 (1999) 242-251
22. Scher H.I., Buchanan G., Gerald W., et al. Targeting the androgen receptor: Improving outcomes for castration-resistant prostate cancer. Endocrinol Relat Cancer 11 (2004) 459-476
23. Scher H.I., and Sawyers C.L. Biology of progressive, castration-resistant prostate cancer: Directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23 (2005) 8253-8261
24. Labrie F., Dupont A., Belanger A., et al. New hormonal therapy in prostatic carcinoma: Combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5 (1982) 267-275
25. Caubet J.F., Tosteson T.D., Dong E.W., et al. Maximum androgen blockade in advanced prostate cancer: A meta-analysis of published randomized controlled trials using nonsteroidal antiandrogens. Urology 49 (1997) 71-78
26. Schmitt B., Bennett C., Seidenfeld J., et al. Maximal androgen blockade for advanced prostate cancer. Cochrane Database Syst Rev (2000) CD001526
27. Singh S.M., Gauthier S., and Labrie F. Androgen receptor antagonists (anti-androgens): Structure-activity relationships. Curr Med Chem 7 (2000) 211-247
28. Kolvenbag G.J., Furr B.J., and Blackledge G.R. Receptor affinity and potency of non-steroidal antiandrogens: Translation of preclinical findings into clinical activity. Prostate Cancer Prostatic Dis 1 (1998) 307-314
29. Greenberg E. Endocrine therapy in the management of prostatic cancer. Clin Endocrinol Metab 9 (1980) 369-381
30. Robinson M.R., Shearer R.J., and Fergusson J.D. Adrenal suppression in the treatment of carcinoma of the prostate. Br J Urol 46 (1974) 555-559
31. Harris K.A., Weinberg V., Bok R.A., et al. Low dose ketoconazole with replacement doses of hydrocortisone in patients with progressive androgen independent prostate cancer. J Urol 168 (2002) 542-545
32. Shearer R.J., Hendry W.F., Sommerville I.F., et al. Plasma testosterone: An accurate monitor of hormone treatment in prostatic cancer. Br J Urol 45 (1973) 668-677
33. Small E.J., Halabi S., Dawson N.A., et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: A phase III trial (CALGB 9583). J Clin Oncol 22 (2004) 1025-1033
34. Holzbeierlein J., Lal P., LaTulippe E., et al. Gene expression analysis of human prostate carcinoma during hormonal therapy identifies androgen-responsive genes and mechanisms of therapy resistance. Am J Pathol 164 (2004) 217-227
35. Labrie F. Adrenal androgens and intracrinology. Semin Reprod Med 22 (2004) 299-309
36. Belanger B., Belanger A., Labrie F., et al. Comparison of residual C-19 steroids in plasma and prostatic tissue of human, rat and guinea pig after castration: Unique importance of extratesticular androgens in men. J Steroid Biochem 32 (1989) 695-698
37. Mizokami A., Koh E., Fujita H., et al. The adrenal androgen androstenediol is present in prostate cancer tissue after androgen deprivation therapy and activates mutated androgen receptor. Cancer Res 64 (2004) 765-771
38. Miyamoto H., Yeh S., Lardy H., et al. δ5-Androstenediol is a natural hormone with androgenic activity in human prostate cancer cells. Proc Natl Acad Sci USA 95 (1998) 11083-11088
39. Koh E., Kanaya J., and Namiki M. Adrenal steroids in human prostatic cancer cell lines. Arch Androl 46 (2001) 117-125
40. Harper M.E., Pike A., Peeling W.B., et al. Steroids of adrenal origin metabolized by human prostatic tissue both in vivo and in vitro. J Endocrinol 60 (1974) 117-125
41. Montgomery B., Mostaghel E., Vessella R., et al. Androgen synthesis in castration-adapted metastatic prostate cancer. J Clin Oncol 25 (2007) 98 (2007 ASCO Annual Meeting Proceedings).
42. Koh E., Noda T., Kanaya J., et al. Differential expression of 17beta-hydroxysteroid dehydrogenase isozyme genes in prostate cancer and noncancer tissues. Prostate 53 (2002) 154-159
43. Ashida S., Nakagawa H., Katagiri T., et al. Molecular features of the transition from prostatic intraepithelial neoplasia (PIN) to prostate cancer: Genome-wide gene expression profiles of prostate cancers and PINs. Cancer Res 64 (2004) 5963-5972
44. Fung K.M., Samara E.N., Wong C., et al. Increased expression of type 2 3alpha-hydroxysteroid dehydrogenase/type 5 17 β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocrinol Relat Cancer 13 (2006) 169-180
45. Auchus R.J. The backdoor pathway to dihydrotestosterone. Trends Endocrinol Metab 15 (2004) 432-438
46. Small E.J., Baron A.D., Fippin L., et al. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal. J Urol 157 (1997) 1204-1207
47. Attard G., Belldegrun A.S., and de Bono J.S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96 (2005) 1241-1246
48. Handratta V.D., Vasaitis T.S., Njar V.C., et al. Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: Synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. J Med Chem 48 (2005) 2972-2984
49. Ryan C.J. Phase I evaluation of abiraterone acetate (CB7630), a 17alpha hydroxylase C17,20-lyase inhibitor in androgen-independent prostate cancer (AiPC). J Clin Oncol Part 1 (2007) 5064 (2007 ASCO Annual Meeting Proceedings)
50. Attard G. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRPC) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. J Clin Oncol Part 1 (2007) 5063 (2007 ASCO Annual Meeting Proceedings)
51. Berube M., and Poirier D. Chemical synthesis and in vitro biological evaluation of a phosphorylated bisubstrate inhibitor of type 3 17β-hydroxysteroid dehydrogenase. J Enzyme Inhib Med Chem 22 (2007) 201-211
52. Spires T.E., Fink B.E., Kick E.K., et al. Identification of novel functional inhibitors of 17β-hydroxysteroid dehydrogenase type III (17β-HSD3). Prostate 65 (2005) 159-170
53. Stanway S.J., Purohit A., Woo L.W., et al. Phase I study of STX 64 (667 Coumate) in breast cancer patients: The first study of a steroid sulfatase inhibitor. Clin Cancer Res 12 (2006) 1585-1592
54. Klein H., Molwitz T., and Bartsch W. Steroid sulfate sulfatase in human benign prostatic hyperplasia: Characterization and quantification of the enzyme in epithelium and stroma. J Steroid Biochem 33 (1989) 195-200
55. Nakamura Y., Suzuki T., Fukuda T., et al. Steroid sulfatase and estrogen sulfotransferase in human prostate cancer. Prostate 66 (2006) 1005-1012
56. Samson D.J., Seidenfeld J., Schmitt B., et al. Systematic review and meta-analysis of monotherapy compared with combined androgen blockade for patients with advanced prostate carcinoma. Cancer 95 (2002) 361-376